Total trials
217
Active
92
Phase 3
66
Total enrollment
285,767
Pipeline matrix
Showing 40 of 117 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Pembrolizumab | — | — | — | — | 7 | ||
| FOLFOX regimen | — | — | — | — | 7 | ||
| Capecitabine | — | — | — | — | 12 | ||
| Trastuzumab | — | — | — | — | 7 | ||
| oxaliplatin | — | — | — | — | 17 | ||
| paclitaxel | — | — | — | 8 | |||
| Chemotherapy | — | — | — | 7 | |||
| cisplatin | — | — | — | 14 | |||
| methotrexate | — | — | — | — | 3 | ||
| Zanidatamab | — | — | — | — | 2 | ||
| Encorafenib | — | — | — | — | 2 | ||
| Binimetinib | — | — | — | — | 2 | ||
| Darolutamide 300 mg | — | — | — | — | — | 2 | |
| Androgen deprivation therapy | — | — | — | — | — | 2 | |
| Standard of care | — | — | — | — | — | 2 | |
| Atezolizumab | — | — | — | — | 2 | ||
| docetaxel | — | — | — | — | 14 | ||
| etoposide | — | — | — | — | 7 | ||
| ifosfamide | — | — | — | — | 6 | ||
| Gemcitabine | — | — | — | — | — | 4 | |
| doxorubicin hydrochloride | — | — | — | — | 4 | ||
| Cabazitaxel | — | — | — | — | 3 | ||
| Darolutamide | — | — | — | — | 2 | ||
| Everolimus | — | — | — | — | 2 | ||
| abiraterone acetate | — | — | — | — | 2 | ||
| Chemotherapy followed by endocrine therapy and ribociclib treatment | — | — | — | — | — | 1 | |
| Futibatinib | — | — | — | — | — | 1 | |
| Ivosidenib | — | — | — | — | — | 1 | |
| Neratinib | — | — | — | — | — | 1 | |
| Niraparib | — | — | — | — | — | 1 | |
| ADT | — | — | — | — | — | 1 | |
| HORMONOTHERAPY | — | — | — | — | — | 1 | |
| CHEMOTHERAPY then HORMONOTHERAPY | — | — | — | — | — | 1 | |
| zoledronic acid | — | — | — | — | — | 1 | |
| HIPEC | — | — | — | — | — | 1 | |
| test-directed treatment: allocated treatment will depend on the PAM50 score result (centrally assessed) : chemo-endocrine therapy or endocrine therapy alone | — | — | — | — | — | 1 | |
| In the control arm, the treatment will be as standard of care : chemo-endocrine therapy | — | — | — | — | — | 1 | |
| Reduced dose intensity of IO | — | — | — | — | — | 1 | |
| mFOLFOX regimen | — | — | — | — | — | 1 | |
| Mitazalimab | — | — | — | — | — | 1 |
77 more active programs hidden
Next readouts
- 2015-12
- 2019-05-07
- 2020-06
- 2021-08-18
- 2022-03
- 2022-04-11
- 2022-12
- 2023-01-08
- 2023-11-15
- 2024-08-18
Top conditions
- Breast Cancer30
- Colorectal Cancer15
- Prostate Cancer13
- Metastatic Breast Cancer10
- Metastatic Colorectal Cancer8
- Metastatic Cancer6
- Sarcoma5
- Head and Neck Cancer5
Frequently asked questions about UNICANCER
- How many clinical trials does UNICANCER have on ClinicalTrials.gov?
- UNICANCER is listed as the lead sponsor on 217 clinical trials in ClinicalTrials.gov, 92 of which are currently active (recruiting, enrolling, or ongoing).
- How many of UNICANCER's trials are in Phase 3?
- 66 of UNICANCER's trials are in Phase 3, spread across 117 active drug programs.
- What therapeutic areas does UNICANCER focus on?
- UNICANCER's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Colorectal Cancer, Prostate Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer.
- When are UNICANCER's next clinical trial readouts?
- UNICANCER has 10 upcoming primary-completion readouts tracked here; the soonest is “Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma”, expected around 2015-12.